Home The $10 Billion Reason That This Tiny Biotech Stock Could Soar
 

Keywords :   


The $10 Billion Reason That This Tiny Biotech Stock Could Soar

2015-02-22 17:00:08| Biotech - Topix.net

If Portola can demonstrate that betrixaban can control bleeding in hospital and post-discharge patients, it could become a big player in the $10 billion market for anticoagulants. Displacing a long-standing leader Warfarin has been used for decades by doctors to help keep blood flowing freely in heart disease and post-operative patients.

Tags: stock reason billion tiny

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.10Eastern North Pacific Tropical Weather Outlook
05.10Atlantic Tropical Weather Outlook
05.10Weekly Recap: BASF, Beckers, Allnex, Sherwin-Williams Top This Weeks Stories
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 24
05.10Hurricane Kirk Wind Speed Probabilities Number 24
05.10Hurricane Kirk Forecast Advisory Number 24
05.10Hurricane Kirk Public Advisory Number 24
More »